Plant Name: Physocarpus intermedius
Taxonomic Information:
Plant ID: NPO5052
Plant Latin Name: Physocarpus intermedius
Taxonomy Genus: Physocarpus
Taxonomy Family: Rosaceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| CDK6; | |
| CA2; CA1; CA7; CA4; CA12; CA9; | |
| HSD17B10; CBR1; AKR1B1; | |
| HIF1A; | |
| ABCG2; | |
| XDH; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | CBR1 | Carbonyl reductase [NADPH] 1 | P16152 | CHEMBL5586 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.730E-14 | 1.256E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.739E-13 | 7.573E-10 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.028E-12 | 3.731E-09 | CA1, CA12, CA2, CA4, CA7, CA9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.151E-12 | 6.692E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, XDH |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.707E-12 | 9.895E-09 | CA1, CA12, CA2, CA4, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.252E-11 | 2.530E-08 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.394E-11 | 2.530E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.302E-11 | 3.581E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.431E-11 | 4.669E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 4.114E-10 | 3.583E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.794E-09 | 2.430E-06 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.076E-07 | 1.027E-04 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.659E-06 | 7.225E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 2.431E-06 | 9.987E-04 | CYP19A1, CYP1A2, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.054E-06 | 1.146E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 3.054E-06 | 1.146E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 4.179E-06 | 1.517E-03 | AKR1B1, CYP19A1, CYP1A2, XDH |
| BP | GO:0050896; response to stimulus | GO:0010035; response to inorganic substance | 5.283E-06 | 1.826E-03 | AKR1B1, CA2, CYP1A1, CYP1A2, CYP1B1, HIF1A |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 6.104E-06 | 2.014E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.017E-05 | 3.255E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0016614; oxidoreductase activity, acting on CH-OH group of donors | 1.044E-05 | 3.293E-03 | AKR1B1, CBR1, HSD17B10, XDH |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.524E-05 | 4.546E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 1.524E-05 | 4.546E-03 | CA1, CA2 |
| BP | GO:0008152; metabolic process | GO:0022900; electron transport chain | 2.080E-05 | 6.121E-03 | AKR1B1, CYP19A1, CYP1A2, XDH |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 2.132E-05 | 6.191E-03 | CYP1A2, CYP3A4 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 2.458E-05 | 6.861E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 2.841E-05 | 7.831E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0042446; hormone biosynthetic process | 3.288E-05 | 8.949E-03 | AKR1B1, CYP19A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.676E-15 | 2.914E-11 | CA1, CA12, CA2, CA4, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 5.365E-15 | 2.629E-13 | CA12, CA1, CA2, CA4, CA7, CA9 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.113E-12 | 2.727E-11 | CYP2C9, CBR1, CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP2C19 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 7.135E-11 | 1.165E-09 | CYP2C9, CBR1, CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.578E-09 | 3.159E-08 | CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP19A1 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 8.374E-08 | 6.839E-07 | CYP2C9, CBR1, CYP1A2, CYP1A1, AKR1B1, CYP2C19, CYP3A4, CYP19A1, HSD17B10, XDH |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.699E-08 | 1.665E-07 | CYP2C9, CYP1A2, CYP3A4, CYP2C19 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 4.733E-07 | 3.313E-06 | CYP2C9, CYP1A2, CYP1A1, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 6.028E-07 | 3.692E-06 | CYP2C9, CYP1A2, CYP3A4, CYP2C19 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 8.252E-06 | 4.493E-05 | CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.627E-05 | 7.246E-05 | CYP1A1, CYP1B1, CYP19A1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 3.115E-05 | 1.272E-04 | CYP2C9, CBR1, CYP2C19 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 4.680E-05 | 1.764E-04 | CA2, CYP3A4, ABCG2 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00983 | Drug metabolism - other enzymes | 9.577E-04 | 3.128E-03 | CYP3A4, XDH |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 2.374E-04 | 8.307E-04 | CA2, CA4 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 9.483E-06 | 4.647E-05 | CYP1A2, XDH |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | CBR1; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
